Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.49 |
| ▸ | TERT | O14746 | 5/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | RRM1 | P23921 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8540142 | 1.00 | GNAI3 (0.50) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL16615963 | 0.96 | GNAI3 (0.47) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL3896673 | 0.90 | GNAI3 (0.42) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL5697801 | 0.90 | GNAI3 (0.42) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL30531774 | 0.90 | GSR (0.42) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL30880423 | 0.88 | GNAI3 (0.45) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL847121 | 0.87 | GNAI3 (0.44) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL847122 | 0.87 | GNAI3 (0.44) | GNAI3GNAO1GNAI1GSRTERT | |
| SCHEMBL7781619 | 0.85 | GSR (0.58) | GNAI3GNAO1GNAI1GSRMMP2 | |
| SCHEMBL1641744 | 0.85 | GSR (0.58) | GNAI3GNAO1GNAI1GSRMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | claimed |
| US-5750555-A | NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | claimed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | claimed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | claimed |
| EP-3897693-B1 | SYNTHETIC AND RECOMBINANT COLLAGEN PEPTIDES HAVING BIOLOGICAL ACTIVITY | GELITA AG (DE) | 2025-08-06 | — | — | EP | disclosed |
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2025-05-22 | — | — | US | disclosed |
| CN-120005928-A | Dynamic regulation and control system, strain, construction method of strain and application of strain in microbial fuel cell | 天津科技大学 | 2025-05-16 | — | — | CN | disclosed |
| US-12128110-B2 | Transglutaminase conjugation method and linker | PAUL SCHERRER INSTITUT (CH) | 2024-10-29 | — | — | US | disclosed |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | PAUL SCHERRER INSTITUT (CH) | 2024-10-24 | — | — | US | disclosed |
| US-5750555-A | NERVOUS SYSTEM DISORDERS; SKIN DISORDERS; IMMUNOLOGY | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1998-05-12 | — | — | US | disclosed |
| EP-0674632-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014798-A1 | AMINOACID DERIVATIVES OF HETEROCYCLES AS PROTEIN KINASE C INHIBITORS | Gödecke Aktiengesellschaft (DE) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161479-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | GNAI3 2786/4885GNAO1 1653/4885GNAI1 2788/4885 |
| US-12128110-B2 | Transglutaminase conjugation method and linker | TGM3, TGM2, TGM1 | GNAI3 2512/4885GNAO1 1420/4885GNAI1 2579/4885 |
| US-20240350656-A1 | TRANSGLUTAMINASE CONJUGATION METHOD AND LINKER | TGM3, TGM2, TGM1 | GNAI3 2590/4885GNAO1 1504/4885GNAI1 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.